2021
New Heart Failure After Myocardial Infarction (From the National Cardiovascular Data Registries [NCDR] Linked With All-Payer Claims)
Faridi KF, Bhalla N, Atreja N, Venditto J, Khan ND, Wilson T, Fonseca E, Shen C, Yeh RW, Secemsky EA. New Heart Failure After Myocardial Infarction (From the National Cardiovascular Data Registries [NCDR] Linked With All-Payer Claims). The American Journal Of Cardiology 2021, 151: 70-77. PMID: 34053629, DOI: 10.1016/j.amjcard.2021.04.019.Peer-Reviewed Original ResearchConceptsIncident heart failureChronic kidney diseaseAcute myocardial infarctionAdvanced chronic kidney diseaseConcurrent heart failureRecurrent myocardial infarctionHeart failureMyocardial infarctionRisk scoreNational Cardiovascular Data Registry CathPCIChest Pain-MI RegistryHistory of HFNew-onset heart failureTime of MINew heart failureSimplified risk scoreOnset heart failureIndex myocardial infarctionFuture heart failureAfrican American raceSpecific risk factorsCumulative incidenceIndependent predictorsKidney diseaseRisk factorsLack of Guideline-Directed Medical Therapy in Patients Undergoing Endovascular Procedures for Critical Limb Ischemia
Llanos-Chea F, Jelani QU, Trejo-Paredes C, Curtis JP, Parzynski CS, Huang J, Faridi KF, Turner J, Smolderen KG, Mena-Hurtado C. Lack of Guideline-Directed Medical Therapy in Patients Undergoing Endovascular Procedures for Critical Limb Ischemia. Journal Of The American College Of Cardiology 2021, 77: 1374-1375. PMID: 33706882, DOI: 10.1016/j.jacc.2020.12.063.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsCohort StudiesEndovascular ProceduresFemaleGuideline AdherenceHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIschemiaMaleMiddle AgedPeripheral Arterial DiseasePlatelet Aggregation Inhibitors
2020
Left Ventricular Systolic Function and Inpatient Mortality in Patients Hospitalized with Coronavirus Disease 2019 (COVID-19)
Faridi KF, Hennessey KC, Shah N, Soufer A, Wang Y, Sugeng L, Agarwal V, Sharma R, Sewanan LR, Hur DJ, Velazquez EJ, McNamara RL. Left Ventricular Systolic Function and Inpatient Mortality in Patients Hospitalized with Coronavirus Disease 2019 (COVID-19). Journal Of The American Society Of Echocardiography 2020, 33: 1414-1415. PMID: 32951969, PMCID: PMC7442910, DOI: 10.1016/j.echo.2020.08.016.Peer-Reviewed Original ResearchInpatient Transthoracic Echocardiography during the COVID-19 Pandemic: Evaluating a New Triage Process
Hennessey KC, Shah N, Soufer A, Wang Y, Agarwal V, McNamara RL, Crandall I, Balan S, Pereira J, Kim Y, Hur DJ, Velazquez EJ, Sugeng L, Faridi KF. Inpatient Transthoracic Echocardiography during the COVID-19 Pandemic: Evaluating a New Triage Process. Journal Of The American Society Of Echocardiography 2020, 33: 1418-1419. PMID: 32888760, PMCID: PMC7392041, DOI: 10.1016/j.echo.2020.07.018.Peer-Reviewed Original ResearchPhysician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment–Elevation Myocardial Infarction in the United States
Faridi KF, Garratt KN, Kennedy KF, Maddox TM, Secemsky EA, Butala NM, Yeh RW. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment–Elevation Myocardial Infarction in the United States. Circulation Cardiovascular Quality And Outcomes 2020, 13: e006275. PMID: 32156164, DOI: 10.1161/circoutcomes.119.006275.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiologistsCardiology Service, HospitalClopidogrelDrug UtilizationFemaleHemorrhageHumansMaleMiddle AgedPatient DischargePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPractice Patterns, Physicians'Prasugrel HydrochloridePurinergic P2Y Receptor AntagonistsReceptors, Purinergic P2Y12RegistriesRetrospective StudiesRisk AssessmentRisk FactorsST Elevation Myocardial InfarctionTicagrelorTime FactorsTreatment OutcomeUnited StatesConceptsST-segment elevation myocardial infarctionP2Y12 inhibitor usePotent P2Y12 inhibitorsP2Y12 inhibitorsSTEMI patientsMyocardial infarctionInhibitor useClopidogrel usePrior percutaneous coronary interventionNew P2Y12 inhibitorsSubstantial hospital variationUse of ticagrelorElevation myocardial infarctionPercutaneous coronary interventionRisk of deathStrongest clinical predictorsNational utilization ratesBackground TicagrelorHospital quartilesCoronary interventionPatient characteristicsClinical predictorsTicagrelor useHospital variationRetrospective study
2019
Comparing different assessments of remnant lipoprotein cholesterol: The very large database of lipids
Faridi KF, Quispe R, Martin SS, Hendrani AD, Joshi PH, Brinton EA, Cruz DE, Banach M, Toth PP, Kulkarni K, Jones SR. Comparing different assessments of remnant lipoprotein cholesterol: The very large database of lipids. Journal Of Clinical Lipidology 2019, 13: 634-644. PMID: 31320236, DOI: 10.1016/j.jacl.2019.06.001.Peer-Reviewed Original ResearchConceptsLow-density lipoprotein cholesterolRemnant lipoprotein cholesterolLipoprotein cholesterolLipid parametersVertical auto profile ultracentrifugationRLP-C levelsAtherosclerotic cardiovascular diseaseLipid panelMedian ageHighest quintileRisk factorsCardiovascular diseaseSecond quintileFriedewald equationCholesterolQuintileDlRLPParameters correlatesSubject differencesLipidsCohortDisease
2018
Chest Pain During Chemotherapy: A Case of Severe Myocardial Bridging.
Mukhopadhyay A, Faridi KF, Asnani A, Osborn EA, Yang JX, Phillips CT, York M. Chest Pain During Chemotherapy: A Case of Severe Myocardial Bridging. Journal Of Invasive Cardiology 2018, 30: e61. PMID: 29958181, PMCID: PMC6247798.Peer-Reviewed Case Reports and Technical NotesUtilization, In-Hospital Mortality, and 30-Day Readmission After Percutaneous Mitral Valve Repair in the United States Shortly After Device Approval
Faridi KF, Popma JJ, Strom JB, Shen C, Choi E, Yeh RW. Utilization, In-Hospital Mortality, and 30-Day Readmission After Percutaneous Mitral Valve Repair in the United States Shortly After Device Approval. The American Journal Of Cardiology 2018, 121: 1365-1372. PMID: 29627105, DOI: 10.1016/j.amjcard.2018.02.016.Peer-Reviewed Original ResearchConceptsPercutaneous mitral valve repairMitral valve repairValve repairHospital volumeClinical comorbiditiesReduced hospital readmissionsHospital mortality rateDays of dischargeIn-Hospital MortalityNationwide Readmissions DatabaseAdministrative claims databaseHospital readmission ratesRoutine clinical practiceDevice approvalCause mortalityHospital deathMultivariable adjustmentPatient demographicsReadmission ratesHospital readmissionMitraClip deviceClaims databaseHospital characteristicsRisk factorsProcedural volume
2017
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy
Hess GP, Natarajan P, Faridi KF, Fievitz A, Valsdottir L, Yeh RW. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy. Circulation 2017, 136: 2210-2219. PMID: 29084735, PMCID: PMC5716860, DOI: 10.1161/circulationaha.117.028430.Peer-Reviewed Original ResearchMeSH KeywordsAdministrative Claims, HealthcareAgedAtherosclerosisCost-Benefit AnalysisDrug CostsElectronic Health RecordsEligibility DeterminationFemaleHumansHyperlipoproteinemia Type IIHypolipidemic AgentsInsurance, Health, ReimbursementInsurance, Pharmaceutical ServicesMaleMedicareMiddle AgedPCSK9 InhibitorsProcess Assessment, Health CareProprotein Convertase 9Retrospective StudiesSerine Proteinase InhibitorsTreatment OutcomeUnited StatesConceptsProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsAtherosclerotic cardiovascular diseasePCSK9i prescriptionsPayer typeCardiovascular diseaseProprotein convertase subtilisin/kexin type 9 inhibitor therapyHigher low-density lipoprotein cholesterol levelsSubtilisin/kexin type 9 inhibitorsLow-density lipoprotein cholesterol levelsClinical atherosclerotic cardiovascular diseaseDrug's high costNonprimary care providersLipoprotein cholesterol levelsDescriptive cohort studyElectronic medical recordsPCSK9i therapyPrescription approvalThird-party payersStatin useClinical characteristicsStatin intoleranceCohort studyInhibitor therapyPharmacy claimsPrescription claimsSerum vitamin D and change in lipid levels over 5 y: The Atherosclerosis Risk in Communities study
Faridi KF, Zhao D, Martin SS, Lupton JR, Jones SR, Guallar E, Ballantyne CM, Lutsey PL, Michos ED. Serum vitamin D and change in lipid levels over 5 y: The Atherosclerosis Risk in Communities study. Nutrition 2017, 38: 85-93. PMID: 28526388, PMCID: PMC5443111, DOI: 10.1016/j.nut.2017.01.008.Peer-Reviewed Original ResearchConceptsIncident dyslipidemiaLipid changesLongitudinal community-based studyAdjusted average differencesDemographic-adjusted modelsLipid-lowering therapySerum vitamin DCommunity-based studyBaseline dyslipidemiaLipid trendsIncident useCardiovascular riskClinical characteristicsSD ageVitamin DARIC studyAtherosclerosis RiskCardiovascular diseaseLipid levelsDyslipidemiaCommunity studyRatio of TCHDLMixed effects modelsBaseline
2016
Angiotensin II antagonism is associated with reduced risk for gastrointestinal bleeding caused by arteriovenous malformations in patients with left ventricular assist devices
Houston BA, Schneider AL, Vaishnav J, Cromwell DM, Miller PE, Faridi KF, Shah A, Sciortino C, Whitman G, Tedford RJ, Stevens GR, Judge DP, Russell SD, Rouf R. Angiotensin II antagonism is associated with reduced risk for gastrointestinal bleeding caused by arteriovenous malformations in patients with left ventricular assist devices. The Journal Of Heart And Lung Transplantation 2016, 36: 380-385. PMID: 28169115, DOI: 10.1016/j.healun.2016.12.016.Peer-Reviewed Original ResearchConceptsLeft ventricular assist deviceGastrointestinal bleedingAngiotensin II antagonismARB therapyVascular endothelial growth factorArteriovenous malformationsVentricular assist deviceAssist deviceAngiotensin receptor blocker therapyContinuous-flow Left Ventricular Assist DevicesAssociation of ACEIReceptor blocker therapyInternational normalized ratioRegression hazard modelGastrointestinal arteriovenous malformationsJohns Hopkins HospitalLogistic regression analysisRisk of AVMAngiotensin II SignalingEndothelial growth factorBlocker therapyRenal functionAdult patientsBlood pressureCardiomyopathy etiology
2015
Remnant Lipoprotein Cholesterol and Mortality After Acute Myocardial Infarction: Further Evidence for a Hypercholesterolemia Paradox From the TRIUMPH Registry
Martin SS, Faridi KF, Joshi PH, Blaha MJ, Kulkarni KR, Khokhar AA, Maddox TM, Havranek EP, Toth PP, Tang F, Spertus JA, Jones SR. Remnant Lipoprotein Cholesterol and Mortality After Acute Myocardial Infarction: Further Evidence for a Hypercholesterolemia Paradox From the TRIUMPH Registry. Clinical Cardiology 2015, 38: 660-667. PMID: 26459191, PMCID: PMC4715617, DOI: 10.1002/clc.22470.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkersChi-Square DistributionCholesterolFemaleHumansHypercholesterolemiaKaplan-Meier EstimateLinear ModelsLipoproteinsMaleMiddle AgedMyocardial InfarctionProportional Hazards ModelsProspective StudiesProtective FactorsRegistriesRisk AssessmentRisk FactorsTime FactorsTriglyceridesUnited StatesUp-RegulationConceptsAcute myocardial infarctionHigh RLP-C levelsRLP-C levelsRemnant lipoprotein cholesterolLipoprotein cholesterolHazard ratioMyocardial infarctionAcute Coronary Events (GRACE) scoreIntermediate-density lipoprotein cholesterolLow-density lipoprotein cholesterolLipoprotein cholesterol subfractionsMortality 2 yearsUnknown protective factorsLead-time biasRegression hazard ratiosTriglyceride-rich lipoproteinsPrior observational studiesTRIUMPH registryCholesterol subfractionsLowest tertileAMI outcomesAMI survivorsHypercholesterolemic patientsMiddle tertileGlobal RegistryDeficient serum 25-hydroxyvitamin D is associated with an atherogenic lipid profile: The Very Large Database of Lipids (VLDL-3) study
Lupton JR, Faridi KF, Martin SS, Sharma S, Kulkarni K, Jones SR, Michos ED. Deficient serum 25-hydroxyvitamin D is associated with an atherogenic lipid profile: The Very Large Database of Lipids (VLDL-3) study. Journal Of Clinical Lipidology 2015, 10: 72-81.e1. PMID: 26892123, PMCID: PMC4762185, DOI: 10.1016/j.jacl.2015.09.006.Peer-Reviewed Original ResearchConceptsLow-density lipoprotein cholesterolIntermediate-density lipoprotein cholesterolAtherogenic lipid profileLipoprotein cholesterolRemnant lipoprotein cholesterolLipid profileLipid panelHigh-density lipoprotein cholesterolMultivariable-adjusted linear regressionVitamin D supplementationHigher total cholesterolSerum vitamin DCardiovascular disease riskLow serum HDLBlood urea nitrogenCross-sectional studyMultivariable linear regressionAdditional outcome measurementD supplementationGlycemic statusLow HDLHemoglobin A1cTotal cholesterolKidney functionSerum HDLRelationship of the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio to the remainder of the lipid profile: The Very Large Database of Lipids-4 (VLDL-4) study
Quispe R, Manalac RJ, Faridi KF, Blaha MJ, Toth PP, Kulkarni KR, Nasir K, Virani SS, Banach M, Blumenthal RS, Martin SS, Jones SR. Relationship of the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio to the remainder of the lipid profile: The Very Large Database of Lipids-4 (VLDL-4) study. Atherosclerosis 2015, 242: 243-250. PMID: 26232164, DOI: 10.1016/j.atherosclerosis.2015.06.057.Peer-Reviewed Original ResearchConceptsHigh-density lipoprotein cholesterol ratioLipoprotein cholesterol ratioLipid profileLDL densityCholesterol ratioAtherogenic lipid phenotypeLevels of RLPMedian TgMetabolic syndromeLipid parametersCohort representativeInsulin resistanceMean ageStudy populationElevated TGGeneral U.S.Higher RLPUS individualsLipid phenotypesDemographic informationHighest relative increaseTriglyceridesRLPAgeRelative increase
2014
Comparing 3-T multiparametric MRI and the Partin tables to predict organ-confined prostate cancer after radical prostatectomy
Gupta RT, Faridi KF, Singh AA, Passoni NM, Garcia-Reyes K, Madden JF, Polascik TJ. Comparing 3-T multiparametric MRI and the Partin tables to predict organ-confined prostate cancer after radical prostatectomy. Urologic Oncology Seminars And Original Investigations 2014, 32: 1292-1299. PMID: 24863013, DOI: 10.1016/j.urolonc.2014.04.017.Peer-Reviewed Original ResearchConceptsNegative predictive valuePositive predictive valueOrgan-confined prostate cancerExtracapsular extensionOC diseasePartin tablesRadical prostatectomyClinical stageProstate cancerPredictive valueMedian prostate-specific antigen levelProstate-specific antigen levelMultiparametric magnetic resonance imagingHigh negative predictive valueHigh positive predictive valueBiopsy Gleason scoreInstitutional review board approvalAvailable clinical parametersDigital rectal examinationSeminal vesicle invasionHigher prognostic accuracyProstate cancer treatmentReview board approvalMagnetic resonance imagingLogistic regression models
2013
Quantitative dynamic contrast-enhanced MRI of pelvic and lumbar bone marrow: effect of age and marrow fat content on pharmacokinetic parameter values.
Breault SR, Heye T, Bashir MR, Dale BM, Merkle EM, Reiner CS, Faridi KF, Gupta RT. Quantitative dynamic contrast-enhanced MRI of pelvic and lumbar bone marrow: effect of age and marrow fat content on pharmacokinetic parameter values. American Journal Of Roentgenology 2013, 200: w297-303. PMID: 23436875, DOI: 10.2214/ajr.12.9080.Peer-Reviewed Original ResearchAdipose TissueAdolescentAdultAgedAged, 80 and overAgingBone MarrowContrast MediaFemaleHumansLumbar VertebraeMagnetic Resonance ImagingMaleMeglumineMetabolic Clearance RateMiddle AgedOrgan SpecificityOrganometallic CompoundsPelvic BonesReproducibility of ResultsSensitivity and SpecificityTissue DistributionYoung Adult